Annunziata Corteggio

Annunziata Corteggio

Auto-generated profile, based on publicly available information

Annunziata Corteggio

Institute of Biochemistry and Cell Biology (IBBC); National Reasearch Council (CNR), Via Pietro Castellino, National Reasearch Council (CNR)

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in The Veterinary Journal
Verified
Journal Article
Closed access
Marcus BatistaMarcus Batista
Marcus Batista
Maria Angélica Ramos SilvaMaria Angélica Ramos Silva
Maria Angélica Ramos Silva
NPNayara E. Pontes
Nayara E. Pontes
MRMarcio C. Reis
Marcio C. Reis
ACAnnunziata Corteggio
Annunziata Corteggio
Antonio Carlos de FreitasAntonio Carlos de Freitas
Antonio Carlos de Freitas

12 January 2015 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
FBFlorentina Daraban Bocaneti
Florentina Daraban Bocaneti
GAGennaro Altamura
Gennaro Altamura
ACAnnunziata Corteggio
Annunziata Corteggio
EVElena Velescu
Elena Velescu
GBGiuseppe Borzacchiello
Giuseppe Borzacchiello
Bovine cutaneous fibropapillomas are benign hyperproliferative lesions induced by Bovine Papillomaviruses (BPVs). Bcl-2 is an important anti-apoptotic protein which is expressed in several cancer types. In contrary, p53 is a tumour suppressor protein that mediates cell cycle arrest, apoptosis and senescence in response to cellular stresses. Here, we investigated immunohistochemically and biochemically, the expression of bcl-2 and p53 in a subset of BPV positive fibropapillomas and bovine normal skin. Normal skin samples showed a weak signal for both proteins in the cytoplasm of the basal cells. Nine out of twelve (75%) tumour samples stained positive for bcl-2 throughout basal and parabasal layers, with most of cells showing strong cytoplasmic immunoreactivity. Nine out of twelve (75%) fibropapillomas were found to be positive for p53 expression, showing a strong cytoplasmic and perinuclear staining of p53 protein mainly in the basal and parabasal layers. Our data reveal an altered bcl-2 and p53 immunoreactivity in bovine cutaneous fibropapillomas, suggesting involvement of these two proteins in the cutaneous neoplastic transformation through an impaired apoptotic process.

26 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnnunziata Corteggio
Annunziata Corteggio
MMMatteo Lo Monte
Matteo Lo Monte
LSLaura Schembri
Laura Schembri
NDNina Dathan
Nina Dathan
SPSimone Di Paola
Simone Di Paola
Daniela CordaDaniela Corda
Daniela Corda
The GTPase Rab14 is localized at the trans-Golgi network and at the intermediate compartment associated to sorting/recycling endosomes-like structures of the transferrin-recycling pathway: as other Rab family members, it is involved in the regulation of intracellular vesicle trafficking, though its role and functional relationship with effector/endosomal proteins is still incomplete. We have analysed whether post-translational modifications could affect Rab14 activity: the results obtained define mono-ADP-ribosylation (MARylation) as the yet-unknown Rab14 modification, catalysed by the ADP-ribosyltransferase PARP12, which specifically modifies glutamic acid residues in position 159/162. This modification is essential for the Rab14-dependent endosome progression. Accordingly, recycling of the transferrin receptor is inhibited when MARylation of Rab14 is prevented by PARP12 knocking-down or inhibition, or by overexpression of Rab14 ADP-ribosylation-defective mutant. Under these conditions, Rab14 and transferrin receptors are withheld at the cell periphery at the level of the Rab4-RUFY1-positive sorting endosomes, indicating that the interaction of Rab14 with the dual effectors RUFY and then FIP1c (which specifically binds both Rab11 and Rab14) determines the progression between the Rab4-RUFY- and Rab11-FIP1c-specific vesicles. Therefore Rab14-MARylation determines the sequential binding of this GTPase to RUFY and FIP1c, thus controlling endosome progression ( i . e ., transferrin receptors recycling) through the Rab4-, Rab14- and Rab11-specific vesicles. This identifies a Rab14-specific compartment of the recycling pathway and a crucial enzymatic reaction amenable to pharmacological control.